[{"id":"85a83785-b733-4534-88fe-4b08d1977f8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04126070","created_at":"2021-01-18T20:09:27.547Z","updated_at":"2025-02-25T14:28:48.143Z","phase":"Phase 2","brief_title":"Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors","source_id_and_acronym":"NCT04126070","lead_sponsor":"Xiao X. Wei, MD","biomarkers":" PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/11/2020","start_date":" 05/11/2020","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-29"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"d08e3cfd-4eeb-458a-9218-3225ed8135e4","acronym":"NePtune","url":"https://clinicaltrials.gov/study/NCT05498272","created_at":"2022-09-18T06:19:44.875Z","updated_at":"2025-02-25T15:00:34.026Z","phase":"Phase 2","brief_title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","source_id_and_acronym":"NCT05498272 - NePtune","lead_sponsor":"Rana McKay, MD","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-10-24"},{"id":"79775896-981f-4795-860c-5b8a8ca129f9","acronym":"ADEPT","url":"https://clinicaltrials.gov/study/NCT04569747","created_at":"2021-01-18T21:49:27.045Z","updated_at":"2025-02-25T12:27:45.281Z","phase":"Phase 2","brief_title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","source_id_and_acronym":"NCT04569747 - ADEPT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 375","initiation":"Initiation: 01/11/2021","start_date":" 01/11/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-10-01"},{"id":"cf8bf0b5-ca6f-4f6e-a44f-54ab88c53b60","acronym":"FACILE","url":"https://clinicaltrials.gov/study/NCT03944434","created_at":"2021-01-18T19:25:17.328Z","updated_at":"2025-02-25T15:43:30.551Z","phase":"Phase 2","brief_title":"FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT03944434 - FACILE","lead_sponsor":"Fondazione Sandro Pitigliani","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • anastrozole • triptorelin • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 12/27/2018","start_date":" 12/27/2018","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 11/27/2025","study_completion_date":" 11/27/2025","last_update_posted":"2024-09-25"},{"id":"4004e195-6fa4-408f-8f56-450ccd6489c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06528210","created_at":"2025-02-25T16:02:53.341Z","updated_at":"2025-02-25T16:02:53.341Z","phase":"Phase 2","brief_title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06528210","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bicalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-30"},{"id":"9fe0152c-72e1-4a52-bb9d-c984450578a4","acronym":"ARCH","url":"https://clinicaltrials.gov/study/NCT05700903","created_at":"2023-01-26T15:02:58.180Z","updated_at":"2024-07-02T16:34:26.941Z","phase":"Phase 4","brief_title":"Contributions to Hypertension With Androgen Deprivation Therapy","source_id_and_acronym":"NCT05700903 - ARCH","lead_sponsor":"University of Colorado, Denver","biomarkers":" LCN2","pipe":"","alterations":" ","tags":["LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • bicalutamide • goserelin acetate • flutamide • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 09/20/2023","start_date":" 09/20/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-06-12"},{"id":"dae7e1e4-54ce-455f-95d9-b6fe1e15a02c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01194271","created_at":"2021-01-18T04:46:46.549Z","updated_at":"2025-02-25T14:32:19.111Z","phase":"Phase 2","brief_title":"Neoadjuvant Ipilimumab in Prostate Cancer","source_id_and_acronym":"NCT01194271","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • CD4 • ICOS","pipe":"","alterations":" ","tags":["CD8 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2024-06-06"},{"id":"1315f5e9-3b04-4aab-a843-bdf4b3d84f6e","acronym":"SNARE","url":"https://clinicaltrials.gov/study/NCT05593497","created_at":"2022-10-25T13:56:29.819Z","updated_at":"2024-07-02T16:34:59.265Z","phase":"Phase 2","brief_title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","source_id_and_acronym":"NCT05593497 - SNARE","lead_sponsor":"VA Office of Research and Development","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Truqap (capivasertib) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2024","start_date":" 05/31/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-06-04"},{"id":"43fbfbcb-f326-4024-95a0-b6bf5afd97c2","acronym":"DETECT V","url":"https://clinicaltrials.gov/study/NCT02344472","created_at":"2021-01-18T11:08:55.334Z","updated_at":"2025-02-25T13:34:30.541Z","phase":"Phase 3","brief_title":"Detect V / CHEVENDO (Chemo vs. Endo)","source_id_and_acronym":"NCT02344472 - DETECT V","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-06-04"},{"id":"9d36eb56-f83b-4bb5-b4f9-f5bad74fda43","acronym":"ADJUVANT WIDER","url":"https://clinicaltrials.gov/study/NCT05827081","created_at":"2023-04-24T14:04:09.161Z","updated_at":"2024-07-02T16:35:07.923Z","phase":"Phase 3","brief_title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","source_id_and_acronym":"NCT05827081 - ADJUVANT WIDER","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Suspended","enrollment":" Enrollment 3100","initiation":"Initiation: 02/28/2024","start_date":" 02/28/2024","primary_txt":" Primary completion: 09/07/2029","primary_completion_date":" 09/07/2029","study_txt":" Completion: 09/20/2030","study_completion_date":" 09/20/2030","last_update_posted":"2024-04-24"},{"id":"953f54f6-a015-4470-87c6-8327cbe57fac","acronym":"PH002-TP-II","url":"https://clinicaltrials.gov/study/NCT03272477","created_at":"2021-01-17T17:20:14.947Z","updated_at":"2025-02-25T13:52:22.823Z","phase":"Phase 2","brief_title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","source_id_and_acronym":"NCT03272477 - PH002-TP-II","lead_sponsor":"Palleos Healthcare GmbH","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • tamoxifen • Perjeta (pertuzumab) • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 257","initiation":"Initiation: 10/05/2017","start_date":" 10/05/2017","primary_txt":" Primary completion: 07/14/2020","primary_completion_date":" 07/14/2020","study_txt":" Completion: 03/04/2024","study_completion_date":" 03/04/2024","last_update_posted":"2024-04-17"},{"id":"b6b913f3-7f35-4ce1-9c9a-7dd7e84a43df","acronym":"BYLieve","url":"https://clinicaltrials.gov/study/NCT03056755","created_at":"2021-01-17T17:15:56.950Z","updated_at":"2024-07-02T16:35:12.604Z","phase":"Phase 2","brief_title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","source_id_and_acronym":"NCT03056755 - BYLieve","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • letrozole • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 379","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 07/17/2025","study_completion_date":" 07/17/2025","last_update_posted":"2024-03-27"},{"id":"3389546b-7889-41d7-a623-1ac7e9ef8f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05924256","created_at":"2023-06-29T14:09:00.727Z","updated_at":"2024-07-02T16:35:14.639Z","phase":"Phase 2","brief_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","source_id_and_acronym":"NCT05924256","lead_sponsor":"Fudan University","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-03-15"},{"id":"1bd14822-da3c-4dbb-9782-85f6d5deab4b","acronym":"PREDICT-RT","url":"https://clinicaltrials.gov/study/NCT04513717","created_at":"2021-01-18T21:37:58.373Z","updated_at":"2024-07-02T16:35:20.440Z","phase":"Phase 3","brief_title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","source_id_and_acronym":"NCT04513717 - PREDICT-RT","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 2478","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2033","primary_completion_date":" 12/31/2033","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2024-02-07"},{"id":"516b31f5-466c-4410-8cae-2fcf87e0c0c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01746849","created_at":"2021-01-18T07:39:24.877Z","updated_at":"2024-07-02T16:35:24.333Z","phase":"Phase 2","brief_title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT01746849","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34 • CD4","pipe":" | ","alterations":" Chr t(15;17)","tags":["CD34 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-05"},{"id":"b59747c0-577f-45fd-a561-b2bbf5411fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT01674140","created_at":"2021-01-18T07:14:46.881Z","updated_at":"2024-07-02T16:35:25.687Z","phase":"Phase 3","brief_title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT01674140","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1939","initiation":"Initiation: 09/12/2013","start_date":" 09/12/2013","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-12-20"},{"id":"0a4f94d2-46dc-4d75-9e6a-d30cc9f79e51","acronym":"CASPAR","url":"https://clinicaltrials.gov/study/NCT04455750","created_at":"2023-12-09T16:53:24.247Z","updated_at":"2024-07-02T16:35:27.217Z","phase":"Phase 3","brief_title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","source_id_and_acronym":"NCT04455750 - CASPAR","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Rubraca (rucaparib) • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 05/15/2024","primary_completion_date":" 05/15/2024","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-04"},{"id":"abd152fd-e9de-4edb-ba07-f0552fdf5de0","acronym":"CompLEEment-1","url":"https://clinicaltrials.gov/study/NCT02941926","created_at":"2021-01-17T17:23:19.146Z","updated_at":"2024-07-02T16:35:31.877Z","phase":"Phase 3","brief_title":"Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC","source_id_and_acronym":"NCT02941926 - CompLEEment-1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 3246","initiation":"Initiation: 11/30/2016","start_date":" 11/30/2016","primary_txt":" Primary completion: 11/08/2019","primary_completion_date":" 11/08/2019","study_txt":" Completion: 11/09/2022","study_completion_date":" 11/09/2022","last_update_posted":"2023-10-24"},{"id":"c88bd8d2-1222-406c-ba31-c677f4047764","acronym":"ASCLEPIuS","url":"https://clinicaltrials.gov/study/NCT04194554","created_at":"2021-07-05T17:26:59.721Z","updated_at":"2024-07-02T16:35:37.018Z","phase":"Phase 1/2","brief_title":"A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer","source_id_and_acronym":"NCT04194554 - ASCLEPIuS","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" DRD","pipe":" | ","alterations":" DDR • DRD","tags":["DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DDR • DRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-09-14"},{"id":"aa82c999-b4a7-457e-bd30-3de1ee970f2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03900637","created_at":"2021-01-18T19:12:25.372Z","updated_at":"2024-07-02T16:35:41.783Z","phase":"Phase 2","brief_title":"PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate","source_id_and_acronym":"NCT03900637","lead_sponsor":"Seoul National University Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • letrozole • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 11/08/2019","start_date":" 11/08/2019","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-07-27"},{"id":"d68c21bc-30b1-4db8-a332-083cde839ded","acronym":"CARABELA","url":"https://clinicaltrials.gov/study/NCT04293393","created_at":"2021-01-18T20:49:58.372Z","updated_at":"2024-07-02T16:35:42.612Z","phase":"Phase 2","brief_title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","source_id_and_acronym":"NCT04293393 - CARABELA","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • Verzenio (abemaciclib) • cyclophosphamide • letrozole • pegylated liposomal doxorubicin • goserelin acetate • leuprolide acetate for depot suspension • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/02/2020","start_date":" 10/02/2020","primary_txt":" Primary completion: 06/21/2023","primary_completion_date":" 06/21/2023","study_txt":" Completion: 02/28/2033","study_completion_date":" 02/28/2033","last_update_posted":"2023-07-19"},{"id":"882858bc-bf0c-4b8e-8282-55dda7614200","acronym":"ASPAIT","url":"https://clinicaltrials.gov/study/NCT02914158","created_at":"2021-01-18T14:18:24.029Z","updated_at":"2024-07-02T16:35:57.555Z","phase":"Phase 3","brief_title":"Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women","source_id_and_acronym":"NCT02914158 - ASPAIT","lead_sponsor":"First Affiliated Hospital, Sun Yat-Sen University","biomarkers":" ER","pipe":" | ","alterations":" ER positive • HR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 03/30/2016","start_date":" 03/30/2016","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-01-16"},{"id":"863f301c-d7ce-401c-a561-44e816aa2de5","acronym":"BOOSTER","url":"https://clinicaltrials.gov/study/NCT01989780","created_at":"2021-01-18T09:04:26.431Z","updated_at":"2024-07-02T16:36:06.061Z","phase":"Phase 2","brief_title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","source_id_and_acronym":"NCT01989780 - BOOSTER","lead_sponsor":"Japan Breast Cancer Research Group","biomarkers":" HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2022-08-04"}]